Resverlogix spins out epigenetics to enable buyout
This article was originally published in Scrip
Executive Summary
Investors above and below the US-Canadian border were unenthused by Resverlogix's 8 April disclosure that the Canadian company would spin its early-stage drug development pipeline out as a publicly-traded subsidiary to make itself more attractive to buyers.